Comparison of in Vitro Activity of Doripenem versus Old Carbapenems against Pseudomonas Aeruginosa Clinical Isolates from both CF and Burn Patients
- 1 June 2013
- journal article
- research article
- Vol. 3 (1) , 121-125
Abstract
Purpose: The antimicrobial activity of doripenem in comparison of imipenem, meropenem and ertapenem among Pseudomonas aeruginosa isolated from burn and Cystic Fibrosis (CF) patients were determined. Methods: Metallo-beta-lactamase (MBL) genes in imipenem non susceptible P. aeruginosa isolates were detected using PCR method. The in vitro susceptibilities of doripenem, imipenem, meropenem and ertapenem were determined by Etests. MIC50 and MIC90 for corresponding antibiotics were determined individually in burn and CF isolates. Results: Among isolates which were resistant to imipenem, 16 isolates were positive for the bla (IMP) gene. All isolates had no bla (VIM) gene. All MBL producing isolates were excluded. MIC50/MIC90 of doripenem in CF and burn isolates were 0.75/>32 and >32/>32 mg/L respectively. The corresponding values for imipenem in CF and burn isolates were 2/>32 and >32/>32 mg/L, respectively. Conclusion: The susceptibility rate of doripenem is higher than that of imipenem and meropenem among P. aeruginosa isolated from CF patients, whereas, there is no difference between the efficiency of doripenem and old carbapenems in non MBL producing P. aeruginosa isolates in burn patients.Keywords
This publication has 17 references indexed in Scilit:
- DoripenemClinical Infectious Diseases, 2009
- Antimicrobial activities of doripenem and other carbapenems against Pseudomonas aeruginosa, other nonfermentative bacilli, and Aeromonas spp.Diagnostic Microbiology and Infectious Disease, 2009
- Challenges in Identifying New Antimicrobial Agents Effective for Treating Infections with Acinetobacter baumannii and Pseudomonas aeruginosaClinical Infectious Diseases, 2006
- Interplay of Efflux System, ampC , and oprD Expression in Carbapenem Resistance of Pseudomonas aeruginosa Clinical IsolatesAntimicrobial Agents and Chemotherapy, 2006
- In Vitro Activity of Doripenem against Pseudomonas aeruginosa and Burkholderia cepacia Isolates from both Cystic Fibrosis and Non-Cystic Fibrosis PatientsAntimicrobial Agents and Chemotherapy, 2006
- Carbapenem resistance mechanisms in Pseudomonas aeruginosa: alterations of porin OprD and efflux proteins do not fully explain resistance patterns observed in clinical isolatesAPMIS, 2005
- Multidrug resistance associated with mexXY expression in clinical isolates of Pseudomonas aeruginosa from a Texas hospitalDiagnostic Microbiology and Infectious Disease, 2004
- In VitroAntibacterial Activity of S-4661, a New Parenteral Carbapenem, against Urological Pathogens Isolated from Patients with Complicated Urinary Tract InfectionsJournal of Chemotherapy, 2002
- Of Pseudomonas, porins, pumps and carbapenemsJournal of Antimicrobial Chemotherapy, 2001
- Carbapenem Resistance Mechanisms in Pseudomonas aeruginosa Clinical IsolatesAntimicrobial Agents and Chemotherapy, 2001